1218 related articles for article (PubMed ID: 15747152)
1. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
3. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.
Mosconi L; De Santi S; Li Y; Li J; Zhan J; Tsui WH; Boppana M; Pupi A; de Leon MJ
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):210-21. PubMed ID: 16311757
[TBL] [Abstract][Full Text] [Related]
4. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
[TBL] [Abstract][Full Text] [Related]
5. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
[TBL] [Abstract][Full Text] [Related]
6. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
[TBL] [Abstract][Full Text] [Related]
7. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization.
Küntzelmann A; Guenther T; Haberkorn U; Essig M; Giesel F; Henze R; Schroeter ML; Schröder J; Schönknecht P
Neurosci Lett; 2013 Feb; 534():12-7. PubMed ID: 23182881
[TBL] [Abstract][Full Text] [Related]
8. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.
Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC
BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082
[TBL] [Abstract][Full Text] [Related]
9. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
[TBL] [Abstract][Full Text] [Related]
10. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
[TBL] [Abstract][Full Text] [Related]
11. Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.
Habeck C; Risacher S; Lee GJ; Glymour MM; Mormino E; Mukherjee S; Kim S; Nho K; DeCarli C; Saykin AJ; Crane PK;
Brain Imaging Behav; 2012 Dec; 6(4):568-83. PubMed ID: 23179062
[TBL] [Abstract][Full Text] [Related]
12. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
[TBL] [Abstract][Full Text] [Related]
13. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
[TBL] [Abstract][Full Text] [Related]
15. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
Mosconi L; Tsui WH; De Santi S; Li J; Rusinek H; Convit A; Li Y; Boppana M; de Leon MJ
Neurology; 2005 Jun; 64(11):1860-7. PubMed ID: 15955934
[TBL] [Abstract][Full Text] [Related]
16. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
[TBL] [Abstract][Full Text] [Related]
17. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
Drzezga A; Lautenschlager N; Siebner H; Riemenschneider M; Willoch F; Minoshima S; Schwaiger M; Kurz A
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
[TBL] [Abstract][Full Text] [Related]
18. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
20. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
